NC/Nga 마우스에서의 아토피피부염 모델 개발 및 피부염 병변에 대한 다래 추출물(Actinidia Extract)의 효과 = Developing an Atopic Dermatitis Model and the Effects of Actinidia Extract on Dermatitis in NC/Nga MiceNC/Nga 마우스에서의 아토피피부염 모델 개발 및 피부염 병변에 대한 다래 추출물(Actinidia Extract)의 효과

다국어 초록 (Multilingual Abstract)

Background: Atopic dermatitis is a chronic itchy, inflammatory skin disease that usually relapses. Although the etiology of atopic dermatitis remains unclear, it has been shown that both Th1 and Th2 cytokines play pathogenic roles in the generation of atopic dermatitis. DA-9102 is a fraction from the Actinidia species and DA-9102 displays immune modulating activity for allergy related disease. Objective: We have developed the atopic dermatitis model of NC/Nga mice using DNCB and we examined whether DA-9102 suppresses the development of atopic dermatitis-like skin lesions on NC/Nga mice. Methods: NC/Nga mice were challenged with DNCB during 5 weeks to develop atopic dermatitis-like skin lesions. Daily DA-9102 or cyclosporine A or HPMC (control) were then given orally. The efficacy of DA-9102 in NC/Nga mice was judged by measurement of the skin lesion severity (a modified SCORAD score), the serum IgE and IgG2a levels and the cytokine levels (IFN-γ and IL-4) from spleen cells cultured with ConA. Results: Atopic dermatitis-like lesions were developed on the NC/Nga mice by using topical DNCB. Oral administration of 100 mg/kg DA-9102 significantly suppressed the development of dermatitis, as was analyzed by a modified SCORAD score (p<0.01). The serum IgE level increased gradually with age, but treatment with DA-9102 suppressed the increment of the serum IgE level (p<0.01). The mean values of IFN-γ in the NC/Nga mice of the DA-9102 group were lower than those of the control mice group (p<0.05). The mean values of IL-4 were undetectable in all the experimental groups. The serum IgG2a level were not significantly different among all the experimental groups. Conclusion: We successfully developed an atopic dermatitis model in NC/Nga mice. Based on our in in vitro data, we suggest that DA-9102 can be useful for the treatment of atopic dermatitis. (Korean J Dermatol 2009;47(10):1105∼1112)

참고문헌 (Reference)

1 Mosmann TR, "Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins" 136 : 2348-2357, 1986

2 Habu Y, "The mechanism of a defective IFN-A response to bacterial toxins in an atopic dermatitis model, NC/Nga mice, and the therapeutic effect of IFN-A, IL-12, or Il-18 on dermatitis" 166 : 5439-5347, 2001

3 Park EJ, "Suppression of spontaneous dermatitis in NC/Nga murine model by PG102 isolated from Actinidia arguta" 127 : 1154-1160, 2007

4 Yoshiaki T, "Repeated topical challenge with chemical antigen elicits sustained dermatitis in NC/Nga mice in specific-pathogen-free condition" 124 : 119-124, 2005

5 Ochi H, "Peripheral blood T lymphocytes and basophils, freshly isolated from house dust mite sensitive patients, produce interleukin-4 in response to allergen-specific stimulation" 111 : 253-261, 1996

6 Horsmanheimo L, "Mast cells are one major source of interleukin-4 in atopic dermatitis" 131 : 348-353, 1994

7 Paul WE, "Lymphokine responses and cytokines" 76 : 241-251, 1994

8 Romagnani S, "Lymphokine production by human T cells in disease states" 12 : 227-257, 1994

9 Scheerens H, "Long-term topical exposure to toluene diisocyanate in mice leads to antibody production and in vivo airway hyperresponsiveness three hours after intranasal challenge" 159 : 1074-1080, 1999

10 Grewe M, "Lesional expression of interferongamma in atopic eczema" 343 : 25-26, 1994

11 Bradding P, "Interleukin 4 is localized to and released by human mast cells" 176 : 1381-1386, 1992

12 Punnonen J, "Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells" 90 : 3730-3734, 1993

13 Kang JS, "Induction of atopic eczema/dermatitis syndrome-like skin lesions by repeated topical application of a crude extract of Dermatophagoides pteronyssinus in NC/Nga mice" 6 : 1616-1622, 2006

14 Aioi A, "Impairment of skin barrier function in NC/Nga Tnd mice as a possible model for atopic dermatitis" 144 : 12-18, 2001

15 Tsudzuki M, "Hiroi J, Matsuda H. Genetic analysis for dermatitis and IgE hyperproduction in the NC/Nga mice" 47 : 88-90, 1997

16 Kuhn R, "Generation and analysis of interleukin-4 deficient mice" 254 : 707-710, 1991

17 Morita E, "Fur mite induce dermatitis associated with IgE hyperproduction in a inbred strain of mice, NC/Kuj" 19 : 37-43, 1999

18 Matsuda H, "Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice" 3 : 461-466, 1996

19 Jujo K, "Decreased interferon gamma and increased interleukin-4 in atopic dermatitis promotes IgE synthesis" 90 : 323-331, 1992

20 Watanabe N, "Chymase inhibitor improves dermatitis in NC/Nga mice" 128 : 229-234, 2002

21 Yoshimoto T, "CD4＋NK1.1＋T cells promptly produce interleukin-4 in response to in vitro challenge with anti-CD3" 179 : 1285-1295, 1994

22 Poulsen LK, "Biomolecular regulation of the IgE immune response. In vitro IgE synthesis and spontaneous production of cytokines" 106 : 55-61, 1995

23 Grewe M, "Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients" 105 : 407-410, 1995

24 Seder RA, "Acquisition of lymphokine-producing phenotype by CD4＋ T cells" 12 : 635-673, 1994

25 Grewe M, "A role for Th1 and Th2 in the immunopathogenesis of atopic dermatitis" 19 : 359-361, 1998

26 Matsukura S, "A effects of TNCB sensitization in DS-Nh mice, Serving as a model of atopic dermatitis, in comparison with NC/Nga mice" 136 : 173-180, 2005